A Flow Cytometric Assay of Platelet Activation Marker P-Selectin (CD62P) Distinguishes Heparin-induced Thrombocytopenia (HIT) from HIT with Thrombosis (HITT)

Summary

Heparin induced thrombocytopenia (HIT) is a well-known complication of heparin administration but usually resolves upon discontinuation without sequelae. However, a small proportion of HIT patients develop thrombosis associated with HIT, designated as HITT, which is often life-threatening and may lead to gangrene and amputations. Existing laboratory methods of confirming HIT/HITT do not distinguish between HIT and HITT. We report a flow cytometric assay of platelet activation marker CD62P to distinguish the effects of addition of HIT vs. HITT plasma to normal blood. Briefly, normal whole blood was incubated with platelet-poor plasma from 12 patients with HITT, 30 with HIT, and 65 controls, in presence and absence of heparin, and expression of CD62P was assayed by flow cytometry. When the ratios of fluorescent intensity of CD62P with heparin divided by that without heparin were compared, HITT plasma induced significantly higher ratios than HIT plasma (HITT ratios ~2.5 vs. HIT ratios ~1.2; p <0.001). Eleven of 12 HITT patients were positive by this test but only 5 of 30 HIT patients were positive (p < 0.0005). In a case of HIT with silent thrombosis, this assay gave a positive results prior to clinically evident thrombosis. In conclusion, this method distinguishes HITT from HIT and may be clinically useful in the detection of HITT, allowing early intervention for preventing catastrophic thrombosis.

Keywords

Heparin-induced thrombocytopenia - thrombosis - thrombocytopenia - drug-induced antibodies - heparin - platelet activation - P-selectin - CD62 - CD36

• References

• 1 Warkentin TE, Kelton JG. Heparin-induced thrombocytopenia. Progr Hemost Thromb 1991; 10: 1-34.
• 2 Chong BH. Heparin-induced thrombocytopenia. Br J Haematol 1995; 89: 431-9.
• 3 Warkentin TE, Chong BH, Greinacher A. Heparin-induced thrombocytopenia: Towards consensus. Thromb Haemost 1998; 79: 1-7.
• 4 Walenga JM, Bick RL. Heparin-induced thrombocytopenia, paradoxical thromboembolism, and other side effects of heparin therapy. Med Clinics North Amer 1998; 82: 635-57.
• 5 Alving BM, Krishnamurti C. Recognition and management of heparin-induced thrombocytopenia (HIT) and thrombosis. Semin Thromb Hemost 1997; 23: 569-74.
• 6 Kelton JG, Warkentin TE. Diagnosis of heparin-induced thrombocytopenia: Still a journey, not yet a destination (Editorial). Amer J Clin Path 1995; 104: 611-3.
• 7 Chong BH, Eisbacher M. Pathophysiology and laboratory testing of heparin-induced thrombocytopenia. Sem Hematol 1998; 35 (04) (Suppl. 05) 3-8.
• 8 Vermylen J, Hoylaerts MF, Arnout J. Antibody-mediated thrombosis. Thromb Haemost 1997; 78: 420-6.
• 9 Amiral J, Bridey F, Dreyfus M, Vissac AM, Fressinaud E, Wolf M, Meyer D. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia (letter). Thromb Haemost 1992; 68: 95-6.
• 10 Greinacher A, Amiral J, Dummel V, Vissac A, Kiefel V, Mueller-Eckhardt C. Laboratory diagnosis of heparin-associated thrombocytopenia and comparison of platelet aggregation test, heparin-induced platelet activation test, and platelet factor 4/heparin enzyme-linked immunosorbent assay. Transfusion 1994; 34: 381-5.
• 11 Amiral J, Bridey F, Wolf M, Boyer-Neumann C, Ftressinaud E, Vissac AM, Paynaud-Debayle E, Dreyfus M, Meyer D. Antibodies to macromolecular platelet factor 4-heparin complexes in heparin-induced thrombocytopenia: a study of 44 cases. Thromb Haemost 1995; 73: 21-8.
• 12 Kelton JG, Smith JW, Warkentin TE, Hayway C, Denomme GA, Horsewood P. Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood 1994; 83: 3232-9.
• 13 Visentin GP, Ford SE, Scott JP, Aster RH. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest 1994; 93: 81-8.
• 14 Arepally G, McKenzie SE, Jiang XM, Poncz M, Cines DB. Fc(gamma) RIIA H/R¹³¹ polymorphism, subclass-specific IgG anti-heparin/platelet factor 4 antibodies and clinical course in patients with heparin-induced thrombocytopenia and thrombosis. Blood 1997; 89: 370-5.
• 15 Kelton JG, Sheridan D, Santos A, Smith J, Steeves K, Smith C, Brown C, Murphy WG. Heparin-induced thrombocytopenia: Laboratory studies. Blood 1988; 72: 925-30.
• 16 Chong BH, Fawaz I, Chesterman CN, Berndt MC. Heparin-induced thrombocytopenia: mechanism of interaction of the heparin-dependent antibody with platelets. Br J Haematol 1989; 73: 235-40.
• 17 Greinacher A, Michels I, Liebenhoff U, Presek P, Mueller-Eckhardt C. Heparin-associated thrombocytopenia: immune complexes are attached to the platelet membrane by the negative charge of highly sulfated oligosaccharides. Br J Haematol 1993; 84: 711-6.
• 18 Sheridan D, Carter CJ, Kelton JC. A diagnostic test for heparin-induced thrombocytopenia. Blood 1986; 67: 27-30.
• 19 Stewart MW, Etches WS, Boshkov LK, Gordon PA. Heparin-induced thrombocytopenia: an improved method of detection based on lumi-aggregometry. Br J Haematol 1995; 91: 173-7.
• 20 Warkentin TE, Hayward CPM, Boshkov LK, Santos AV, Sheppard JAI, Bode AP, Kelton JG. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood 1994; 84: 3691-9.
• 21 Fratantoni JC, Pollet R, Gralnick HR. Heparin-induced thrombocytopenia: confirmation of diagnosis with in vitro methods. Blood 1975; 45: 395-401.
• 22 Chong BH, Burgess J, Ismail F. The clinical usefulness of the platelet aggregation test for the diagnosis of heparin-induced thrombocytopenia. Thromb Haemost 1993; 69: 344-50.
• 23 Larsen E, Celi A, Gilbert GE, Furie BC, Erban JK, Bonfanti R, Wagner DD, Furie B. PADGEM protein: a receptor that mediates the interaction of platelets with neutrophils and monocytes. Cell 1989; 59: 305-12.
• 24 Mao WW, Jy W, Kolodny L, Horstman L, Valant P, Ahn YS. Discrimination of heparin-induced thrombocytopenia (HIT) from HIT with thrombosis (HITT) by flow cytometric analysis of activation marker CD62P. Thromb Haemost 1997; 77 (supl) 448. (Presented at XVI congress of Int Soc Thromb Haemost, June, 1997, Florence, Italy.)
• 25 Mao WW, Jy W, Horstman LL, Valant P, Ahn YS. Flow cytometric assay of P-selectin (CD62P) appears useful in distinguishing heparin induced thrombocytopenia with thrombosis (HITT) from heparin induced thrombocytopenia (HIT). Platelets 1998; 9: 417.
• 26 White MM, Siders L, Jennings LK, White FL. The effect of residual heparin on the interpretation of heparin-induced platelet aggregation in the diagnosis of heparin-associated thrombocytopenia (Letter). Thromb Haemost 1992; 68: 88.
• 27 Jy W, Horstman LL, Park H, Mao WW, Valant P, Ahn YS. Platelet aggregates as markers of platelet activation: Characterization of flow cytometric method suitable for clinical applications. Am J Hematol 1998; 57: 33-42.
• 28 Valant PA, Jy W, Horstman LL, Mao WW, Ahn YS. Thrombotic thrombocytopenic purpura (TTP) plasma enhances platelet-leukocyte interaction in vitro. Br J Haematol 1998; 100: 24-32.
• 29 Arepally G, Reynolds C, Tomaski A, Amiral J, Jawad A, Poncz M, Cines DB. Comparison of PF4 / heparin ELISA assay with the 14-C-serotonin release assay in the diagnosis of heparin-induced thrombocytopenia. Am J Clin Pathol 1995; 104: 648-54.
• 30 Boshkov LK, Warkentin TE, Hayward CPM, Andrew M. Heparin-induced thrombocytopenia and thrombosis: clinical and laboratory studies. Br J Haematol 1993; 84: 322-8.
• 31 Schultz DR, Arnold PI, Jy W, Valant P, Gruber J, Ahn YS, Mao FW, Mao WW, Horstman LL. Anti-CD36 autoantibodies in thrombotic thrombocytopenic purpura and other thrombotic disorders: identification of an 85 kD form of CD36 as a target antigen. Br J Haematol 1998; 103: 849-57.
• 32 Ahn YS, Jy W, Kolodny L, Horstman LL, Mao WW, Valant PA. Activated platelet aggregates in thrombotic thrombocytopenic purpura: decrease with plasma infusions and normalization in remission. Br J Haematol 1996; 95: 408-15.
• 33 Greenwalt DE, Kipsly RH, Ockenhouse CF, Ikeda H, Tandon NN, Jamieson GA. Membrane glycoprotein CD36: A review of its roles in adherence, signal transduction, and transfusion medicine. Blood 1992; 80: 1105-15.
• 34 Amiral J, Marfaing-Koka A, Wolf M, Alessi MC, Tardy B, Boyer-Neumann C, Vissac AM, Fressinaud E, Poncz M, Meyer D. Presence of autoantibodies to interleukin-8 or neutrophil-activating peptide-2 in patients with heparin-associated thrombocytopenia. Blood 1996; 88: 410-6.
• 35 Visentin GP, Moghaddam M, Collins JL, McFarland JG, Aster RH. Antibodies associated with heparin-induced thrombocytopenia (HIT) report conformational changes in platelet factor 4 (PF4) induced by linear polyanionic compounds. Blood 1997; 90 (Suppl. 01) 460a.
• 36 Saffroy R, Bachelot-Loza C, Fridman WH, Aiach M, Teillaud JL, Rendu F. Plasma levels of soluble Fc(gamma) receptors II (sCD32) and III (sCD16) in patients with heparin-induced thrombocytopenia. Thromb Haemost 1997; 78: 970-1.
• 37 Bachelot-Loza C, Saffroy R, Lasne D, Chatellier G, Aiach M, Rendu F. Importance of the Rc(gamma) RII-Arg/His-131 polymorphism in heparin-induced thrombocytopenia diagnosis. Thromb Haemost 1998; 79: 523-8.
• 38 Lee DH, Warkentin TE, Denomme GA, Lagrotteria DD, Kelton JG. Factor V Leiden and thrombotic complications in heparin-induced thrombocytopenia. Thromb Haemost 1998; 79: 50-3.